Anthony M. Maffia III

Anthony M. Maffia III joined Alvotech in 2024. He has over two decades of regulatory affairs experience and leadership in navigating the complex regulatory landscape for biosimilars.

Anthony is responsible for advancing Alvotech‘s biosimilar pipeline through each stage of the approvals process. As Alvotech has established commercial partnerships in over 90 markets globally, this requires attention to minute details of regulations governing biosimilars in different regions and jurisdictions. The regulatory team coordinates these efforts with our R&D and commercial teams, as well as our global partners.

Prior to joining Alvotech, Anthony served as Vice President of Regulatory Affairs, North America for Sandoz and Vice President of Regulatory Affairs, North America for Glenmark. He started his regulatory career at Ranbaxy and then Actavis, as US Regulatory Affairs Manager. Actavis is now part of Teva Pharmaceuticals.  Prior to focusing on regulatory affairs, Anthony worked a research biologist at DuPont Merck Pharmaceuticals utilizing his love of science to identify new drug targets.